Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

September 14, 2021 Auto Bot Clinical Trials, Coherus, Junshi, Non-Small Cell Lung Cancer, P-III, Toripalimab 0

Shots:

  • The P-III CHOICE-01 trial evaluates toripalimab + CT vs CT alone in 465 patients in a ratio (2:1) with advanced sq./nonsq. NSCLC without driver mutations
  • The interim analysis met its 1EPs i.e., improvement in PFS, superior ORR & DoR, OS data are still maturing. The safety profile was consistent with PD-1 inhibitor while final PFS & additional interim OS analyses are expected in later 2021
  • The companies plan to discuss with US FDA for submission of toripalimab’s BLA to treat NSCLC. The therapy has received FTD for mucosal melanoma, ODD for NPC, mucosal melanoma & soft tissue sarcoma, BTD for combination therapy as 1L treatment & for monothx. as 2L treatment of recurrent or metastatic NPC

Click here to read full press release/ article | Ref: Globe Newswire | Image: Coherus

The post Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021 first appeared on PharmaShots.